TBPH logo

THERAVANCE BIOPHARMA INC

TBPHNASDAQ
🏆 #2563 by market capEarnings Nov 9US Equity
$759.75▲ $7.90 (+1.04%)
Simulated price
🔔
Track TBPH
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$884M
Small Cap
📈Revenue Growth (YoY)
+35.1%
High Growth
📊Gross Margin
100.0%
High
💵FCF Margin
269.7%
Strong
⚖️P/S Ratio
8.5x
Elevated
Otter Score
64
Fair
No chart data available for TBPH.

Trading Snapshot

Day Range
$755.91 – $765.04
52-Week Range
$13.08 – $21.03
Volume
$2.42B
Avg Volume
$2.62B
Shares Outstanding
51.8M
Next Earnings
Nov 3, 2026

Fundamentals Snapshot

Annual Revenue
$107M
Last Q Revenue
$21M
P/E Ratio
16.4
P/S Ratio
8.5x
EPS (TTM)
$1.01
Dividend Yield
—
Dilution (1yr)
+7.6%

Why Investors Own TBPH

  • ✓High-growth profile — revenue up +29.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 40% gross margin and 27% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TBPH logo

THERAVANCE BIOPHARMA INC

TBPH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$107M▲ +66.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
94.9%▲ +128.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▼ −71.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$238M▼ −2109.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
53.1M▲ +7.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$92M▲ +$104M YoY
StockOtter · stockotter.space

About THERAVANCE BIOPHARMA INC

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Ratings

ⓘ
Consensus
Buy
11 analysts
Strong Buy2
Buy4
Hold5
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Reuters·2h ago

THERAVANCE BIOPHARMA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift TBPH price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

THERAVANCE BIOPHARMA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.